Ipamorelin

Origin and Structure

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, developed in the late 1990s by Novo Nordisk as part of a program to engineer selective growth hormone secretagogues. It belongs to the class of growth hormone releasing peptides (GHRPs) — compounds that stimulate GH release by binding the ghrelin receptor (GHSR-1a) on somatotropic cells of the anterior pituitary.

What made ipamorelin notable when it was characterized was its unusually clean selectivity profile. Earlier GHRPs — GHRP-6 and GHRP-2 — drive meaningful cortisol, prolactin, and ACTH elevations alongside GH release, and GHRP-6 also triggers substantial appetite stimulation via its ghrelin-mimetic activity. Ipamorelin produces GH release comparable to those compounds at equivalent doses while leaving cortisol, prolactin, and appetite essentially unchanged in published studies.

Mechanism of Action

Ipamorelin acts as an agonist at the ghrelin receptor on pituitary somatotrophs, triggering pulsatile release of growth hormone. This mechanism is distinct from — and complementary to — growth hormone releasing hormone (GHRH) analogues like CJC-1295 and sermorelin, which act at a different receptor (the GHRH receptor) to promote GH synthesis and release.

Because the two pathways work through different receptors and different intracellular signaling cascades, GHRH-analogue plus GHRP combinations produce synergistic rather than additive GH release. This is the rationale behind the widely used ipamorelin + CJC-1295 stack in clinical and research settings — see our detailed stack explainer for the protocol logic.

Clinical Evidence

Ipamorelin was developed through Phase 2 clinical trials in the early 2000s, primarily targeting postoperative ileus — the temporary paralysis of the GI tract that can delay recovery after abdominal surgery. Results in that indication were mixed, and Helsinn Therapeutics (which had acquired development rights) ultimately discontinued the program in 2013. As a result, ipamorelin has never been approved by the FDA for any indication.

Despite the lack of approval, ipamorelin has been studied in several smaller trials and preclinical programs exploring:

• Growth hormone deficiency and adult GH decline. Pharmacokinetic and pharmacodynamic studies have documented consistent GH and IGF-1 elevations in healthy adults.
• Body composition effects. Animal studies and smaller human work have examined effects on lean mass, fat mass, and bone density, broadly consistent with physiological GH elevation.
• Sleep architecture. GH release occurs predominantly during deep (slow-wave) sleep, and some work suggests nighttime GHRP administration may enhance slow-wave sleep duration.

Practical Considerations

Research protocols typically use 100–300 mcg per injection, dosed two to three times daily via subcutaneous injection, often timed to empty-stomach windows. Because ghrelin-receptor activation is blunted by circulating glucose and amino acids, pre-meal or fasting dosing is thought to produce cleaner GH pulses — though the clinical magnitude of this effect is debated.

The ipamorelin + CJC-1295 combination remains the most common stack in community and clinical use, leveraging the synergy between GHRP and GHRH-analogue mechanisms. Some protocols also pair ipamorelin with tesamorelin — a more potent GHRH analogue — though tesamorelin is significantly more expensive and typically reserved for HIV-associated lipodystrophy, its sole FDA-approved indication.

Safety and Regulatory Status

Ipamorelin's tolerability profile in published trials is favorable. The most commonly reported side effects are mild injection-site reactions, transient flushing or tingling at injection, occasional headaches, and — as with any GH secretagogue — water retention, joint stiffness, or carpal tunnel symptoms at higher or sustained dosing. Cortisol and prolactin elevations, which complicate earlier GHRPs, are reported as negligible with ipamorelin.

Ipamorelin is not FDA-approved and is included on the World Anti-Doping Agency (WADA) prohibited list at all times (class S2, Peptide Hormones). It is typically obtained through research-chemical suppliers or compounding pharmacies, with the quality and regulatory caveats that come with that supply chain. For a broader overview of the growth-hormone peptide category, our recovery peptide guide covers how ipamorelin fits alongside the rest of the class.